Forescout's New Risk and Exposure Management Solution Delivers Streamlined, Quantitative Approach to Cyber Asset Risk Management
Forescout, a global leader in cybersecurity, today unveiled Risk and Exposure Management, its cloud-native product designed to collate all data sources associated with an enterprise’s connected assets and calculate a unique multifactor risk score for each asset, offering a more intuitive and quantitative approach to risk prioritization.
Enterprises’ attack surfaces are expanding daily given the technology and business dynamics at play. Security teams realize that existing approaches to cyber asset management can’t effectively scale to meet the diversity of asset types or track configuration and risk posture changes for their assets, making it exceedingly more difficult to conduct expeditiously any incident analysis. The new Risk and Exposure Management solution addresses this challenge by tracking the changes to posture on a unique status-over-time view for every individual asset and enables security teams to act on intuitive cyber risk intelligence, through security workflow automation driven by the Forescout Platform.
According to Forrester, CISOs are readily seeking new approaches to attack surface management that not only better support their teams, but also prove to their boards how they’re reducing risk exposure based on the effectiveness of their security investments. The analyst firm also found that “Among security decision-makers, 73% report that their firm is adopting attack surface management; a further 15% plan to implement it in the next 12 months.”1
“Enterprises require a simplified way to maintain both real-time and persistent asset intelligence for every asset – managed or unmanaged, physical or virtual, including OT/ICS, IoT devices and specialty subsets such as medical devices,” said Barry Mainz, Forescout CEO and President. “We’ve invested heavily in the Forescout Platform, and the enhancements we are making with the availability of Forescout® Risk and Exposure Management provide that intelligence to help security teams effectively prove a reduction in risk posture of their enterprises’ evolving attack surfaces.”
The use cases and benefits of Forescout Risk and Exposure Management are:
- Cybersecurity Asset Management: Discover and classify every device across any environment (90 days retention) to help IT security teams leverage asset context and status trends to streamline their operations.
- Persistent Asset Risk Intelligence: Gain situational awareness of cybersecurity risk posture based on exposure from vulnerabilities and misconfiguration with a unique multifactor risk score.
- Accelerated Incident Response: Leverage historical asset context to aid analysts’ proactive investigation of risks and reactive response to incidents and events to help minimize the blast radius and reduce mean-time-to-resolution (MTTR).
- Enhanced IoT Security: Leverage high-fidelity IoT classification through non-disruptive, passive discovery techniques for deployment flexibility, with real-time identification of xIoT vulnerabilities to help security teams understand the attack surface and prioritize response actions.
- Enhanced Medical Device Security: Clear and concise risk assessment of each connected medical device based on known exposures, attack potential and operational criticality, with insights into FDA class and recall status, to help ensure security without impacting patient care.
In leveraging this product’s capabilities, enterprises can feasibly obtain comprehensive asset intelligence and build a solid foundation for cyber asset attack surface management.
Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats. To learn more, visit www.forescout.com
1 Forrester The State Of Vulnerability Risk Management, 2023 Report - March 15, 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Called Ambassadors From All Around the World to Form “Class of 23”1.10.2023 13:00:00 EEST | Press release
Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231001418878/en/ Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. (Photo: Business Wire) 2023 means a long journey for PUMA, which was made with the remarkable people behind it. “Class of 23” is the right way to celebrate the inspiring ambassadors and talents PUMA has collaborated with over the past 75 years. Each talent, from Neymar Jr. and Pamela Reif to Gianmarco Tamberi and Winnie Harlow, was captured in a personalized way, wearing their favorite PUMA beanies from the 2023 collection to show their membership in the grand PUMA family. “Our PUMA family is the heartbeat of our brand, co-created with the brilliance
Optomind and MaxLinear announce collaboration on PAM4 112Gbps OSFP 800Gbps SR8 transceiver solution at ECOC Exhibition 20231.10.2023 09:00:00 EEST | Press release
Optomind and MaxLinear will be demonstrating 800Gbps OSFP active optical cables (AOC) and SR8 optical transceivers at ECOC 2023 Exhibition, in Glasgow, Scotland, October 2-4 (Booth #775, Optomind; #776, MaxLinear). Optomind has developed the best-in-class PAM4 100Gbps/lane SR optical transceivers and AOCs using MaxLinear's 5nm Keystone PAM4 DSP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230930086952/en/ Advancing data transmission rates to 100Gbps per lane drastically transforms the ecosystem of data centers, especially AI/ML and HPC. Training AI and GPT workloads drive huge and high-density networks utilizing large numbers of servers connected together through rack switches over short reach links. The low-power, high-performance AOCs and transceivers that Optomind and MaxLinear have developed together are ideal for these applications. Optomind selected MaxLinear's 5nm Keystone PAM4 DSP as the best-in-class solution for
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release
GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom